Gram-positive Bacterial Infections Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||921973|
|出版日期||內容資訊||英文 114 Pages
|全球克陽性菌感染疾病市場:成長，趨勢，及預測 Gram-positive Bacterial Infections Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 114 Pages||
The major factor driving the growth of the Gram-positive Bacterial Infections market is the increasing prevalence of the infections because of gram-positive bacteria. Pneumonia is a type of Gram-positive Bacterial Infection that affects the lungs. According to WHO, Pneumonia killed 808 694 children under the age of 5 in 2017, accounting for 15% of all deaths of children under five years old. Pneumonia affects children and families everywhere but is most prevalent in South Asia and Sub-Saharan Africa.
Additionally, increasing product approvals for the treatment of the infections, the rising development of Anti-MRSA drugs are also boosting the market growth globally. In October 2018, Paratek Pharmaceuticals, Inc. received U.S. FDA approval for its NUZYRA (Omadacycline)injection, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). However, antibiotic resistance is the major restraint that is hampering the growth of the market. With the emergence of multidrug-resistant bacteria, antibiotic resistance has become a major concern to global public health. Many antibiotics that have been used to treat infectious diseases are no longer effective, as the pathogens have become resistant to them.
Gram-positive bacteria are among the most common human pathogens associated with clinical infections, which range from mild skin infections to sepsis. Gram-positive Bacterial Infections include Virulence, Pathogenesis, Immune Response, Inflammatory Response, Drug Resistance. There are several classic gram-positive species that cause disease in humans. The most common organisms include Streptococcus, Staphylococcus, Enterococcus, Bacillus, etc.
Cephalosporins segment holds a significant market share
Cephalosporins are beta-lactam antibiotics that inhibit the synthesis of peptidoglycan, present in the cell wall of the bacteria. According to the World Health Organization (WHO), this group of antibiotics is considered as 'critically important to human medicine'.
The cephalosporins are indicated for the treatment of infections caused by Gram-positive bacteria in certain circumstances. These include selected patients with endocarditis, osteomyelitis, septic arthritis, and cellulitis. They are also used as alternatives to the penicillins in penicillin-allergic patients and for 'mixed' infections caused by Gram-positive organisms.
Cephalosporin has a large share in the antibiotics market, which is partly due to overprescription, and also due to the fact that it is the most widely explored family of antibiotics with over five generations of cephalosporins that have already been developed.
Additionally, the companies are involved in the strategic development of new products.
North America Dominates the Market
North America and Europe are the major markets in the Gram-positive Bacterial Infections globally, due to the high prevalence of various types of gram-positive bacterial infections and associated diseases. In the United States, antibiotic use among older adults increased, after insurance coverage was expanded through Medicare Part D, particularly, of broad-spectrum antibiotics. Increasing product launches are anticipated to drive the gram-positive bacterial infections market in the North America region. For instance, in March 2017, Pfizer launched a combination of Avibactam and Ceftazidime drug Zavicefta, for the treatment of intraabdominal infections.
The gram-positive Bacterial Infections market is moderately competitive. The market is comprised of many small and large market players. Some of the market players are GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., etc. among others.
Key developments in the market include: In June 2019, the U.S. Food and Drug Administration approved expanded use of Merck & Co Inc's antibiotic Zerbaxa to treat hospital-acquired pneumonia in patients 18 years and older.